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Background: Shared decision making (SDM) is a model of how doctors and patients interact with each other. It
aims at changing the traditional power asymmetry between doctors and patients by strengthening the exchange
of information and the decisional position of the patient. Although SDM is generally welcomed by mental health
patients as well as by mental health professionals its implementation in routine care, especially in the more acute
settings, is still lacking. SDM-PLUS has been developed as an approach that addresses both patients and mental
health professionals and aims at implementing SDM even for the very acutely ill patients.
Methods: The SDM-PLUS study will be performed as a matched-pair cluster-randomized trial in acute psychiatric
wards. On wards allocated to the intervention group personnel will receive communication training (addressing
how to implement SDM for various scenarios) and patients will receive a group intervention addressing patient
skills for SDM. Wards allocated to the control condition will continue treatment as usual. A total sample size of 276
patients suffering from schizophrenia or schizoaffective disorder on 12 wards is planned.
The main outcome parameter will be patients’ perceived involvement in decision making during the inpatient stay
measured with the SDM-Q-9 questionnaire. Secondary objectives include the therapeutic relationship and long
term outcomes such as medication adherence and rehospitalization rates. In addition, process measures and
qualitative data will be obtained to allow for the analysis of potential barriers and facilitators of SDM-PLUS.
The primary analysis will be a comparison of SDM-Q-9 sum scores 3 weeks after study inclusion (or discharge, if
earlier) between the intervention and control groups. To assess the effect of the intervention on this continuous
primary outcome, a random effects linear regression model will be fitted with ward (cluster) as a random effect
term and intervention group as a fixed effect.
Discussion: This will be the first trial examining the SDM-PLUS approach for patients with schizophrenia or
schizoaffective disorder in very acute mental health inpatient settings. Within the trial a complex intervention will
be implemented that addresses both patients and health care staff to yield maximum effects.
Trial registration: German Clinical Trials Register DRKS00010880. Registered 09 August 2016.
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Shared decision making (SDM) is a model of how doc-
tors and patients interact with each other. It aims at
changing the traditional power asymmetry between doc-
tors and patients by strengthening the exchange of infor-
mation and the decisional position of the patient [1].
While some see the need for SDM from an ethical point
of view [2], others argue that SDM may contribute to
better patient satisfaction and health outcomes [3]. Some
of the basic principles of SDM aim at making the deci-
sion process more explicit by inviting patients to partici-
pate and by clarifying information and participation
preferences. Amongst others, the strategies involve stat-
ing that there is more than one option to choose from
(‘equipoise’), communicating the pros and cons of differ-
ent options and helping patients build their own prefer-
ences (e.g. by administering decision aids) [4, 5].
Although SDM originates from somatic medicine, its
ideas and ideals may be especially important for the field
of mental health where the possibility of involuntary
treatment often creates extreme forms of ‘power asym-
metry’, where the importance of long-term adherence re-
quires special attention for patient satisfaction with the
treatment and where the patients’ potentially handi-
capped decision-making capacity may lead doctors to
avoid practicing SDM [2, 6].
In fact, there is strong evidence that SDM is actually
not really implemented in various mental health settings
[7, 8]. While low implementation of SDM is not unique
for mental health it may be less often implemented com-
pared to other medical fields [9].
Besides the well-known general barriers to SDM [10]
(e.g. time constraints), there may be mental health specific
factors (or factors that may be more pronounced in metal
health settings) that hinder the implementation of SDM.
On the patients’ side, these barriers include, among
others, a lack of interest in decision making (e.g. due to
depressive or negative symptoms) [6, 11], a feeling of
powerlessness in relationship with their providers [11],
or passivity in the medical encounter [12]. On the psy-
chiatrists’ side, reservations to implement SDM are often
founded in doubts regarding patients’ insight and deci-
sional capacity [11, 13, 14]. Here, psychiatrists might be
afraid to make patient outcomes worse by sharing deci-
sions and thereby reaching unreasonable decisions.
The authors have therefore developed a framework for
the implementation of SDM (shared decision making
PLUS, SDM-PLUS [15]) that specifically addresses these
barriers by empowering both patients and providers.
Methods
Rationale
As stated above SDM is not routinely implemented in clin-
ical practice [9, 13] and research on SDM-interventions inmental health setting is limited. Most single interventions
(e.g. SDM training for GPs [16], computerized SDM-tool
[17], web-based tool to support shared decision-making
[18]) have yielded only small effects at best.
Therefore, we argue that it will need a complex inter-
vention (“defined as intervention(s) with several interact-
ing components” [19]) such as SDM-PLUS addressing
both, patients and health care providers to change pat-
terns in medical decision making towards a more partici-
patory atmosphere, especially on acute psychiatric wards.
While the complexity of the intervention is explicitly de-
sired with respect to a strengthening of effects, we have to
acknowledge at the same time the drawbacks of complex
interventions (e.g. the impossibility to trace back effects to
single compounds of the intervention) [20].
To account for these limitations, we will apply a
mixed-methods approach to study process measures and
potential modes of action of the intervention (see
methods for details).
Aim and hypotheses
The aim of the present study is to evaluate the effects of
SDM-PLUS on decision making patterns on acute
psychiatric wards between psychiatrists and patients suf-
fering from schizophrenia. We hypothesize that the
intervention will lead to professionals and patients using
the skills learned in the SDM-PLUS training for profes-
sionals or the SDM-training for patients, respectively,
leading to a higher perceived involvement of patients.
We argue that a better (perceived) involvement of pa-
tients in medical decisions would be a benefit per se [2].
However, a higher perceived involvement from the
patients’ side may also have an effect on the therapeutic
alliance finally resulting in better adherence and fewer
relapses caused by non-adherence [21, 22] (Fig. 1).
The primary objective is to assess if there is a group
difference (intervention vs. control) in patients’ per-
ceived involvement in decision making 3 weeks after
study enrollment (or discharge from the ward, whatever
happens first) using the SDM-Q-9 questionnaire [23].
Trial design
The study is designed as a multi-center, matched-pair
cluster-randomized controlled trial of SDM-PLUS in acute
psychiatric wards addressing inpatients suffering from
schizophrenia or schizoaffective disease. SDM-PLUS will be
implemented in the intervention wards while on the con-
trol wards treatment will be continued as usual (Fig. 2).
Participants
The study will be implemented in 12 acute psychiatric
wards (=clusters) of 5 psychiatric state hospitals. Eligibil-
ity criteria for the wards to be included are: acute psy-
chiatric ward in one of the participating hospitals,
Fig. 1 Potential outcomes of SDM-PLUS
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commonly treated on these wards. The respective wards
have 300–600 admissions per year of which approxi-
mately 20–50% of patients meet inclusion criteria.
All patients fulfilling the inclusion criteria will then be
consecutively recruited for the trial at the time of their
admission to the ward.
Inclusion criteria:Fig. 2 Timeline chart age 18–65 years
 male and female patients
 inpatients of participating hospitals
 diagnosis of schizophrenia or schizoaffective disease
(ICD 10: F20/F25)
 capable of participating in 60 min. group
intervention
 being able to provide written informed consent
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 mental retardation
 insufficient proficiency in German language to
discuss treatment decisions
Intervention and control condition
Treatment teams (consultants, residents, nurses, psy-
chologists and social workers) of intervention wards will
be trained in the SDM-PLUS-approach through partici-
pation in two half-day workshops (within 2 weeks) and
will then be continuously supervised and supported by
the study center over the entire course of the trial
(Fig. 2). The supervision will take the form of weekly
meetings with the physicians in charge. Within these
meetings, a checklist will be completed for every patient
currently participating in the study to review what has
been done to facilitate SDM for this patient (see also the
section “treatment integrity”).
The SDM-PLUS-approach [15] has two basic aims: to
empower health care staff (communication techniques)
and to teach health care staff how to empower patients
(implementation of empowering measures for patients).
Empowerment training for health care staff includes de-
cision analysis and communication strategies about how
to involve patients in medical decisions. Decision ana-
lysis means that health care professionals must analyze
how to best reach shared decision making in every indi-
vidual patient. SDM-PLUS proposes that there are situa-
tions in which SDM can be reached via the “classical
way” (i.e. by discussion pros and cons of several more or
less equivalent options) and that there are situations for
which techniques other than “classical” shared decision
making must be used to reach joint decisions, especially
when there is resistance from the patient’s side. Here,
techniques from the Harvard negotiation model and
from motivational interviewing are taught. Participants
of SDM-PLUS workshops will be presented with “ideal”
courses of action for all three approaches (classical
SDM, preparing for difficult negotiations according to
the Harvard model and reflective listening as an import-
ant aspect of motivational interviewing) and then will
exercise these techniques in supervised role plays.
There is special emphasis on how to successfully ad-
dress “difficult decisions” and avoid underutilization of ef-
fective treatment interventions because of non-addressing
these techniques in discussions with the patient.
The second aim of SDM-PLUS is to empower patients
to be more active partners in medical decision making.
Measures will consist of patient group training in SDM
and the use of question prompt sheets for ward rounds
and individual consultations. The SDM training will be
implemented as a five-session group training [24] (2 ses-
sions per week) that will be led by a member of the studycenter and a member of the respective treatment team to
ensure proper implementation. Within the training pa-
tients will be made familiar with the concept and pros-
pects of SDM and the basic communication skills
necessary to facilitate SDM from the patients’ side. Thus
patients will work out the importance of preparing for
ward rounds, prompting questions and expressing opin-
ions and exercise these skills within role plays and home
works. The SDM training will be offered as an open group
to ensure that patients newly recruited to the study can
immediately participate. The question prompt sheets will
be promoted within the SDM training and implemented
on the wards by nursing staff.
Staff (and patients) of the control wards will act under
“treatment as usual” (TAU) conditions but will be offered
SDM-PLUS-training after the end of the study. In order to
minimize contamination bias (i.e. staff or patients from
control wards getting to know about SDM-PLUS), wards
were selected to ensure that there is no overlap in
personnel and no regular patient transfer between wards.
Outcomes
At all time-points identical data will be collected in the
intervention and control groups (Fig. 2). In our study we
will follow an intention to treat (ITT) approach. There-
fore we will try to follow up all participants in the
12 months periods following hospital discharge irrespec-
tively of whether they are still in treatment or on medi-
cation. We seek for patients’ permission to contact them
directly as well as their actual physicians (if applicable)
at 3/6/9/12 months. By applying this 2-way-approch we
will also be able to approach patients who no longer re-
ceive any kind of psychiatric treatment.
Baseline parameters
For all patients enrolled socio-demographics, diagnosis,
illness severity (CGI and GAF scores) and data on illness
history (previous hospitalizations, duration of illness
etc.) will be recorded at baseline (at study entry).
Since decision making and patients’ perception of de-
cision making may be influenced by patients’ participa-
tion preferences, the Autonomy Preference Index (API
[25]) will be obtained. The API is a four item question-
naire assessing patients’ general desire to participate in
decision making. API scores have been shown to be as-
sociated with treatment satisfaction and health care out-
comes [26]. Further, a recently developed questionnaire
addressing patients’ competence for shared decision
making (PatPart-19) will also be used. This 19 item
questionnaire covers the subscales open communication,
critical communication and adherence in therapy and
was validated in two large samples of psychiatric inpa-
tients (Kohl et al., in preparation). In addition, active pa-
tient decision making has been shown to be related to
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Camberwell Assessment of Need self-report question-
naire (CANSAS-P), a 22-item questionnaire addressing
patients’ needs for support in various domains will be
applied. As SDM-PLUS focusses on critical decision pro-
cesses in which disagreement between patients and phy-
sicians may occur we aim to identify patients with
potentially reduced insight, allowing for subgroup ana-
lyses in patients with or without insight. We will admin-
ister the Birchwood Insight Scale [28], an eight-item
questionnaire addressing insight, necessity of medication
or treatment. Likewise patients’ perception of the
current admission (i.e. the extent to which patients per-
ceived the admission as involuntary) will be recorded
using the MacArthur Admission Experience Survey as
used by O’Donoghue et al. 2013 [29].
Primary outcome
The primary outcome parameter is the patients’ per-
ceived involvement in decision making using the SDM-
Q-9 questionnaire at 3 weeks after enrollment in the
study or discharge (whatever occurs first). Referring to
Rodenburg-Vandenbussche et al. [30] we see a 15 point
difference as clinically meaningful (in the mentioned
study this 15- point difference differentiated between
shared decision making and physician dominated deci-
sion making as perceived by patients) and we expect a
15 point mean difference between the intervention and
control group (Table 1). The SDM-Q-9 refers to a distinct
medical decision which will be the patient’s medication re-
gime, which in many cases is the result of several smaller
decisions during inpatient stay and thereby reflecting the
decision atmosphere between patients and their treating
physicians. Therefore the SDM-Q-9 will serve as a proxy
for inpatient decision making.
Secondary outcomes
As outlined above, a better involvement of patients in
medical decisions and health care professionals better
addressing “difficult decisions” may also result in a bet-
ter therapeutic relationship, higher treatment satisfac-
tion, fewer unmet needs, more thoroughly implemented
therapies, improved adherence, and probable reduced re-
lapse rates (see Fig. 1). These outcomes will be obtained
at T1 (three weeks after study enrolment) and during a
one year follow up with quarterly assessments (T2-T5).
Patients’ involvement in medical decisions from the
patients’ point of view will be obtained as the primary
outcome measure at T1 and as a secondary outcome
during follow up (T2-T5). In addition, physicians will
provide their view on patients’ involvement using the
physician version of the SDM-Q-9 at T2-T5 (SDM-Q-
Doc [31]). As most patients will have changes in their
treating psychiatrist when switching from inpatient tooutpatient treatment, the SDM-Q-9 refers to the in-
patient psychiatrist at T1 and to the outpatient psychia-
trists at T2-T5.
Whether or not the intervention also has an influence
on the therapeutic relationship will be determined using
the Helping Alliance Scale at T2-T5, which has a patient
(HAS-P) and a clinician (HAS-C) version [32]. The HAS
comprises five items rated on a visual analogue scale
ranging from 0 (‘not at all’) to 10 (‘extremely well’).
While HAS-P includes items on ‘right treatment’, ‘under-
stood by therapist’, ‘criticized by therapist’, ‘committed
therapist’ and ‘trust therapist, HAS-C items cover ‘get-
ting along with patient’, ‘understand patient’, ‘look forward
to meeting patient’, ‘feel actively involved’, and ‘feel I can
help patient’.
Treatment satisfaction will be measured using the
Questionnaire on Patients’ Treatment Satisfaction
(ZUF8) at T1, an eight-item questionnaire addressing
general satisfaction with hospital care [33]. The preva-
lence of unmet needs on the patients’ side after interven-
tion will be assessed using the Camberwell Assessment
of Need self-report questionnaire (CANSAS-P) also at
T1 and T2 [34]. For the assessment of adherence, pa-
tients will fill out the Medication Adherence Rating
Scale at T2–T5 (MARS [35]). This measure also in-
cludes the 10 items of the Drug Attitude Inventory
allowing for an analysis of patients’ drug attitudes.
In addition, aspects of patients’ well-being and quality
of life will be addressed using the WHO-5 well-being
index and the EUROHIS-QOL index at T3 and T5. The
WHO-5 index is a five item self-report measure of general
well-being and the EUROHIS-QOL is an 8-item self-
assessment instrument of generic quality of life. Both in-
struments were validated in German versions and yielded
good to excellent psychometric properties [36].
Another aspect of interest is whether or not SDM-
PLUS supports clinicians in addressing “difficult medical
decisions”. This assumption is based on evidence that
the discussion of certain decisions (e.g. long acting anti-
psychotic injectable) is often avoided by psychiatrists
resulting in low implementation rates for these treat-
ments [37]. To document the discussion and implemen-
tation of “difficult medical decisions” we will perform a
semi-structured interview with the psychiatrists in
charge at T1. This interview will – for every patient par-
ticipating in the study - cover four domains: “difficult
compounds”, “difficult other therapies such as ECT”,
“difficult psychosocial interventions such as legal guard-
ianship”, and “difficult other decisions as specified by the
psychiatrist”. For each domain it will be documented
whether or not there was any need for discussing deci-
sions, whether there was a discussion and whether any
decisions were implemented. Data gathered in this inter-
view will result in two “sum scores” of difficult decisions
Table 1 Planned data collection
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In addition, we will obtain at discharge, the length of
the inpatient stay, the future psychiatrist after discharge
and a brief description of discharge medication (antipsy-
chotics prescribed: yes/no, LAI prescribed: yes/no,
monotherapy with antipsychotics vs polypharmacy with an-
tipsychotics: yes/no). Outpatient psychiatrists will be asked
to document any rehospitalization of their patients, theirestimate of the patient’s adherence (one item visual
analogue scale), CGI and GAF scores at T2–T5.
Qualitative data
The rationale behind also obtaining qualitative data is
twofold. First, we would like to get a better insight into
the process and working mode of SDM-PLUS and, sec-
ond, we aim to study the potential barriers and facilita-
tors of SDM-PLUS.
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identify clinical situations of interest (e.g. dissatisfied/
very satisfied patients, decisions with or without patient
participation, patients for whom health staff judges
SDM-PLUS as inappropriate or impossible etc.) and then
perform qualitative interviews with 24 key informants
involved in the trial (physicians, nurses, patients). In
addition, we will perform focus groups with health care
staff after the end of the study to collect their experi-
ences with the intervention. The qualitative part of the
study will take place only on intervention wards and will
be performed by two trained researchers who are work-
ing for the project and are in permanent contact with
patients/staff of the participating hospitals.
The qualitative data will be audio-recorded, tran-
scribed and then analyzed using content analysis [38].
Treatment integrity
To assess treatment adherence we will document: a)
how many of the team members actually receive the
SDM-PLUS training, b) whether there was a change in
attitudes towards SDM (pre-/post-questionnaire), and c)
to what extent single elements of the intervention are
implemented for patients (i.e. use of a “fidelity scale”
during weekly supervision with all physicians in charge).
On the patients’ side, the number of patient intervention
sessions per patient and the percentage of patients re-
ceiving question prompt sheets will be documented.
In addition, we will use a qualitative approach in the
intervention group to assess various aspects of the
process of SDM-PLUS as well as barriers and facilitators
of SDM-PLUS (see “Qualitative data”).
Sample size
The primary analysis will be a comparison of SDM-Q-9
sum scores at T1 between the intervention and control
groups. Referring to Rodenburg-Vandenbussche et al.
2015 [30], a 15 point difference (SD 30) is considered
clinically meaningful. For the study to have 80% power
to detect this mean difference, 23 patients will be re-
cruited in 12 wards, giving a total of 276 patients. This
calculation assumes a two-sided significance level of 5%,
a within-cluster standard deviation of 30, intra-cluster
coefficient of 0.04 and 20% dropout.
Randomization
We will determine pairs of comparable wards (number
of patients, distribution of diagnoses, staff etc.) and then
randomize one ward of each pair to the intervention and
one ward to the control condition (i.e. cluster-
randomization). While the principal investigators will
determine the paired wards, the randomization will be
done by the statistical department of the medical facultyat our university, Institut für Medizinische Statistik und
Epidemiologie (IMSE).
A cluster-randomized design in which the unit of
randomization is the psychiatric ward is seen as neces-
sary to prevent contamination of intervention and con-
trol conditions [19].
Blinding
Due to the nature of the intervention (staff training, pa-
tient training) there will be no blinding. Likewise a
blinding of raters is not applicable because most ratings,
including the main outcome measure, are “subjective”
self-ratings. However, the analysis will be performed by a
statistician who will be blinded as to patient allocation.
To avoid selection bias all patients fulfilling inclusion
criteria will be recruited consecutively in the interven-
tion and control group. This process will be monitored
by the study center and will be reported in form of a
CONSORT diagram. The number of patients who do
not consent will be carefully documented together with
their underlying reason for refusal.
Statistical analyses
To assess the effect of the intervention on the continu-
ous primary outcome, a random effects linear regression
model will be fitted with ward (cluster) as a random ef-
fect term and intervention group as a fixed effect. The
point estimate for the intervention effect will be re-
ported together with the corresponding 95% confidence
interval. A p-value <0.05 will be considered as providing
statistical significant evidence of a group difference. In
addition, models adjusting for baseline covariates such
as severity of illness, admission status and variables with
a large baseline imbalance will be fitted in secondary
analyses. An intention to treat approach will be taken to
the analysis, i.e. patients in intervention clusters will be
analyzed in this group (if outcome data are available)
even if they don’t receive all of the planned intervention.
Exploratory analyses will be performed to assess the
effect of the intervention on the secondary outcome
measures. Furthermore, it will be assessed if SDM is a
mediator for the secondary outcomes following the cri-
teria of Baron and Kenny. Random effect linear models
will be fitted to the continuous secondary outcome
measures, analogous to the primary analysis. For binary
secondary outcome measures, logistic regression models
using GEEs will be fitted.
Ethics, informed consent procedure and trial registration
The trial has been approved by the local review board
(Ethikkommission der Technischen Universität München).
All patients will be informed about the general pur-
pose of the trial (i.e. that decision making patterns
will be compared between different wards) but not about
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and then asked for their informed consent. Following the
trial all patients will be debriefed about the study and the
condition they received. The trial has been registered at
Deutsches Register Klinischer Studien (DRKS00010880).
Discussion
To date, several studies have evaluated interventions to
promote SDM in mental health settings. However, only
few have addressed the very acutely ill patients and most
have had negative results or shown only modest effects.
This will be the first trial examining the SDM-PLUS
approach for patients with schizophrenia or schizoaffec-
tive disorder in very acute mental health inpatient set-
tings. Within the trial a complex intervention will be
implemented that addresses both patients and health
care staff to yield maximum effects. The primary out-
come is patients’ (perceived) involvement in decision
making. Since we expect involvement in decision making
to improve other outcomes such as therapeutic alliance,
adherence and relapse rates, these will be addressed as
secondary outcomes.
It would also have been desirable to have observational
measures of the doctor-patient-communication, as
SDM-PLUS aims at altering communication. However,
since we will study inpatients no clearly definable and
between intervention and control comparable consulta-
tions exist.
Potential methodical limitations may be the extent to
which the proposed strategies are actually implemented
by health care staff and a recruitment bias. We will aim
to minimize these limitations via a thorough assessment
of process measures within a mixed-methods approach
and through recruiting consecutively on all intervention
and control wards. In addition, to avoid for contamin-
ation we do not control for time and attention paid to
patients in the control group and do not offer an active
control condition such as a unspecific group training.
This bears the risk that more attention alone may drive
any changes in perceived SDM. Finally, the main out-
come measure (SDM-Q9) asks for the decision process
that led to the current antipsychotic medication. We
therefore focus on the patients’ perception of SDM with
the prescriber (i.e. psychiatrist) and put less emphasis on
patients’ experiences with other staff members.
The major aim is to show that SDM-PLUS, if thor-
oughly implemented, leads to a higher perceived involve-
ment of patients in medical decision making. While one
might argue that involvement of patients alone might
not constitute a “clinical” or even financial benefit, we
claim that the proof of a better involvement by the intro-
duction of a new communication strategy does have at
least two important implications: It fulfils the wish of
many users of mental health services to be addressed ascompetent individuals (as it is ethically necessary anyhow)
and it would show that being highly symptomatic does
not prevent patients from sharing decisions. Finally, we
hope that – via our secondary outcomes – an additional
value of ethically correct decision making with respect
to a reduction of long term complications (i.e. non-
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